JAK3 and systemic lupus erythematosus: Several therapies are currently in use or under investigation, including Tofacitinib, a JAK1 and JAK3 inhibitor, which, in a phase Ib/IIa trial, appeared to be well-tolerated in 30 patients with SLE, who exhibited a reduction in circulating LDN levels [104,105]; and Idebenone, an antioxidant, which was able to inhibit NETosis in LDNs, attenuating disease manifestation in a murine SLE model [106].